GAIA is focused on the development of evidence-based, safe, and accessible digital therapeutics that help patients restore and maintain their mental and physical health.

Our mission is to develop digital therapeutics offering physicians, therapists, payers, and patients the same effect sizes, safety profiles, and convenience levels as well-developed pharmaceutical solutions.

Our multidisciplinary team includes experienced physicians, psychotherapists, clinical scientists, IT and software engineers, regulatory affairs experts, and market access specialists who cover all competencies required to develop, launch, and maintain top-class products for major markets.

GAIA's digital therapeutics are extensively tested in randomized controlled trials (RCTs). For example, their product deprexis® for depression treatment has been validated in 13 RCTs with effectiveness comparable to antidepressants.